Novel therapies in juvenile idiopathic arthritis

Anne M Sage; Sarah L N Clarke; Athimalaipet V Ramanan

doi:10.1097/BOR.0000000000001028

Novel therapies in juvenile idiopathic arthritis

Anne M Sage, Sarah L N Clarke, Athimalaipet V Ramanan^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

Abstract

Purpose of review
This review summarises the major novel treatment options for children with juvenile idiopathic arthritis (JIA) since the pandemic, reflecting not only on advancements in therapeutics but also approach to management and research.

Recent findings
Several recent international paediatric trials have been important in advancing understanding of JIA and furthering available treatment options. Biologic and small molecule agents were demonstrated to be effective and safe in recalcitrant or severe JIA (including extra-articular complications), mirroring the adult equivalent diseases.

Summary
Although joint and overall health have vastly improved for young people with JIA, ongoing international collaboration, critical review of treatment strategies and high quality research are essential to optimize outcomes.

Original language	English
Pages (from-to)	328-335
Number of pages	8
Journal	Current Opinion in Rheumatology
Volume	36
Issue number	5
DOIs	https://doi.org/10.1097/BOR.0000000000001028
Publication status	Published - 1 Sept 2024

Bibliographical note

Publisher Copyright:
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

Arthritis, Juvenile/drug therapy
Humans
Antirheumatic Agents/therapeutic use
Child
Biological Products/therapeutic use

Access to Document

10.1097/BOR.0000000000001028

Handle.net

Persistent link

Cite this

@article{c2f383888d3349828403693a4ff4acc7,

title = "Novel therapies in juvenile idiopathic arthritis",

abstract = "Purpose of review This review summarises the major novel treatment options for children with juvenile idiopathic arthritis (JIA) since the pandemic, reflecting not only on advancements in therapeutics but also approach to management and research.Recent findings Several recent international paediatric trials have been important in advancing understanding of JIA and furthering available treatment options. Biologic and small molecule agents were demonstrated to be effective and safe in recalcitrant or severe JIA (including extra-articular complications), mirroring the adult equivalent diseases.Summary Although joint and overall health have vastly improved for young people with JIA, ongoing international collaboration, critical review of treatment strategies and high quality research are essential to optimize outcomes.",

keywords = "Arthritis, Juvenile/drug therapy, Humans, Antirheumatic Agents/therapeutic use, Child, Biological Products/therapeutic use",

author = "Sage, {Anne M} and Clarke, {Sarah L N} and Ramanan, {Athimalaipet V}",

year = "2024",

month = sep,

day = "1",

doi = "10.1097/BOR.0000000000001028",

language = "English",

volume = "36",

pages = "328--335",

journal = "Current Opinion in Rheumatology",

issn = "1040-8711",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Novel therapies in juvenile idiopathic arthritis

AU - Sage, Anne M

AU - Clarke, Sarah L N

AU - Ramanan, Athimalaipet V

PY - 2024/9/1

Y1 - 2024/9/1

N2 - Purpose of review This review summarises the major novel treatment options for children with juvenile idiopathic arthritis (JIA) since the pandemic, reflecting not only on advancements in therapeutics but also approach to management and research.Recent findings Several recent international paediatric trials have been important in advancing understanding of JIA and furthering available treatment options. Biologic and small molecule agents were demonstrated to be effective and safe in recalcitrant or severe JIA (including extra-articular complications), mirroring the adult equivalent diseases.Summary Although joint and overall health have vastly improved for young people with JIA, ongoing international collaboration, critical review of treatment strategies and high quality research are essential to optimize outcomes.

AB - Purpose of review This review summarises the major novel treatment options for children with juvenile idiopathic arthritis (JIA) since the pandemic, reflecting not only on advancements in therapeutics but also approach to management and research.Recent findings Several recent international paediatric trials have been important in advancing understanding of JIA and furthering available treatment options. Biologic and small molecule agents were demonstrated to be effective and safe in recalcitrant or severe JIA (including extra-articular complications), mirroring the adult equivalent diseases.Summary Although joint and overall health have vastly improved for young people with JIA, ongoing international collaboration, critical review of treatment strategies and high quality research are essential to optimize outcomes.

KW - Arthritis, Juvenile/drug therapy

KW - Humans

KW - Antirheumatic Agents/therapeutic use

KW - Child

KW - Biological Products/therapeutic use

U2 - 10.1097/BOR.0000000000001028

DO - 10.1097/BOR.0000000000001028

M3 - Review article (Academic Journal)

C2 - 38775143

SN - 1040-8711

VL - 36

SP - 328

EP - 335

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

IS - 5

ER -

Novel therapies in juvenile idiopathic arthritis

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Fingerprint

Cite this